Autophagy in cancer stem/progenitor cells Yi-Hui LinYu-Chun HuangPei-Ming Chu Review Article 26 November 2014 Pages: 879 - 886
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor Kyriakos P. PapadopoulosRandi IsaacsAmit Mahipal Original Article 27 February 2015 Pages: 887 - 895
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study Yogesh T. PatelMegan O. JacusClinton F. Stewart Original Article 28 February 2015 Pages: 897 - 906
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia Jan de JongJuthamas SukbuntherngErik Mannaert Original Article Open access 28 February 2015 Pages: 907 - 916
Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies Yang YuQian ZhaoXiang-Yan Liu Original Article 04 March 2015 Pages: 917 - 922
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model Diane E. ColeCynthia M. Lester-McCullyKatherine E. Warren Original Article 05 March 2015 Pages: 923 - 928
First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy Noa AvisarLiat AdarLaurie Pukac Original Article 05 March 2015 Pages: 929 - 939
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience Roberto PetrioliEdoardo FranciniGiandomenico Roviello Original Article 06 March 2015 Pages: 941 - 947
Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt–Nrf2–HO-1 signaling and reduction of NADPH oxidase Weijun MaJuan HuMin Xu Original Article 07 March 2015 Pages: 949 - 959
Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model Mina KhezrianBehjat SheikholeslamiMohammadreza Rouini Original Article 11 March 2015 Pages: 961 - 968
Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application Zakhar NudelmanMordechai FindlerRakefet Czerninski Original Article 11 March 2015 Pages: 969 - 974
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy Stefanie KraffAnnemieke J. M. NieuweboerMarkus Joerger Original Article 12 March 2015 Pages: 975 - 983
Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer Eiji KuniiTetsuya OguriAkio Niimi Original Article 14 March 2015 Pages: 985 - 991
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer Niall TebbuttDusan KotasekDavid Goldstein Original Article 15 March 2015 Pages: 993 - 1004
Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment Haeng Jung LeeSeung Jun OhTae Won Kim Original Article 17 March 2015 Pages: 1005 - 1013
Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs Miguel MuzzioShu-Chieh HuJan H. Beumer Original Article 17 March 2015 Pages: 1015 - 1023
Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor Inkeun ParkJae-Lyun LeeHanjong Ahn Original Article 17 March 2015 Pages: 1025 - 1035
Dose selection of siltuximab for multicentric Castleman’s disease Christina L. MayerLanyi XieThomas A. Puchalski Original Article 18 March 2015 Pages: 1037 - 1045
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies Margaret von MehrenMichael BookmanRoger B. Cohen Original Article 20 March 2015 Pages: 1047 - 1055
Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in Mice Toru KimuraTakashi NojiriKenji Kangawa Original Article 27 March 2015 Pages: 1057 - 1063
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3 Morten Mau-SørensenChristian DittrichJosep Tabernero Original Article 27 March 2015 Pages: 1065 - 1073
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies Stephen K. WilliamsonGary A. JohnsonCharles J. Decedue Clinical Trial Report 23 April 2015 Pages: 1075 - 1087
Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia Sophia Ingeborg VangKjeld SchmiegelowJacob Nersting Short Communication 19 March 2015 Pages: 1089 - 1093
Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context Ruth Ramos-DíazFernando Gutiérrez-NicolásJosé A Pérez-Pérez Short Communication 25 March 2015 Pages: 1095 - 1098